Amendment to the Misuse of Drugs Act 1975

Regulatory impact statement

Publication Date: 
23 February 2016

This regulatory impact statement analyses the options available for regulating the NBOMe family of hallucinogens. The preferred option involves an amendment to include the substances commonly known as 25B-NBOMe, 25C-NBOMe and 25I-NBOMe in Part 1 of Schedule 2 of the Misuse of Drugs Act 1975. 

Regulatory impact statements

Back to top